Related Experiment Video

Updated: Aug 9, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cell death associated with genetic prodrug activation therapy of colorectal cancer

S Todryk1, A Melcher, G Bottley

  • 1Tumour Immunology Group, Institute for Immunology, Department of Biology, National University of Ireland, Co. Kildare, Maynooth, Ireland. stephen.todryk@may.ie

Cancer Letters
|October 25, 2001
PubMed

Insights

Genetic prodrug activation therapy (GPAT) shows promise for colorectal cancer. Adenoviral delivery of HSVtk to tumor cells enabled ganciclovir-induced death, though bystander effects were minimal, indicating a need for improved gene delivery.

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Genetic prodrug activation therapy (GPAT) is an emerging cancer treatment strategy.
  • Colorectal malignancy is a significant health concern, necessitating novel therapeutic approaches.
  • Laboratory models are crucial for characterizing gene therapies before clinical application.

Purpose of the Study:

  • To investigate the efficacy of GPAT using the Herpes Simplex Virus thymidine kinase (HSVtk) gene delivered via an Adenoviral (Ad) vector in colorectal tumor cells.
  • To evaluate the bystander killing effect of this gene therapy approach.
  • To elucidate the mechanisms of cell death induced by GPAT in colorectal cancer models.

Main Methods:

  • Adenoviral vector-mediated delivery of the HSVtk gene into colorectal tumor cells in vitro.
  • Treatment of transduced cells with the prodrug ganciclovir.
  • Assessment of cell death mechanisms using anti-BrDU and propidium iodide staining.
  • Evaluation of bystander killing in vitro and in vivo.

Main Results:

  • Adenoviral delivery rendered colorectal tumor cells susceptible to ganciclovir-induced cell death, with varying efficacy based on Ad infectability.
  • The bystander killing effect was observed to be minimal in both in vitro and in vivo settings.
  • Cell death mechanisms involved a combination of apoptosis in the G1 phase and late apoptotic or necrotic sub-G1 DNA fragmentation, dependent on the tumor cell line.

Conclusions:

  • GPAT using Ad-mediated HSVtk delivery induces direct cell death in colorectal cancer models.
  • Improvements in Adenoviral transduction efficiency are necessary for enhanced therapeutic outcomes.
  • Potential immune augmentation strategies may be required to further improve the effectiveness of GPAT for colorectal cancer.

More Related Videos

Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy10:03

Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy

Published on: August 2, 2024

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...